Grapefruit Consumption with Statins: Safety Considerations

Mechanism of Interaction

Grapefruit juice inhibits cytochrome P450 3A4 (CYP3A4) enzyme in the intestinal wall, which is responsible for the metabolism of certain statins, leading to increased bioavailability and higher blood levels of these statins 1
Grapefruit juice also inhibits P-glycoprotein (P-gp) transport, which can further increase statin concentrations for statins that are P-gp substrates 1, 2

Patients on atorvastatin should limit grapefruit juice consumption or discuss dose adjustment with their healthcare provider, as grapefruit juice increases blood levels of atorvastatin by approximately 80% 1
Pravastatin, rosuvastatin, fluvastatin, and pitavastatin are not significantly metabolized by CYP3A4 and have minimal interaction with grapefruit juice, with pravastatin and rosuvastatin metabolized primarily by CYP2C9, fluvastatin metabolized primarily by CYP2C9, and pitavastatin having minimal CYP450 metabolism 1

Risk factors for statin-induced myopathy include age >65 years, small body frame and frailty, multisystem disease, multiple medications, and higher statin doses, according to the American College of Cardiology 3

For lomitapide, grapefruit juice is specifically contraindicated as it increases drug exposure significantly, as recommended by the American College of Cardiology 4, 5, 6

For patients on simvastatin or lovastatin, the American Heart Association recommends advising complete avoidance of grapefruit, grapefruit juice, and grapefruit-containing products 1
For patients on atorvastatin, the American Heart Association recommends limiting grapefruit consumption or considering switching to a statin with less interaction potential if the patient regularly consumes grapefruit 1
For patients who cannot avoid grapefruit consumption, the American Heart Association recommends considering using pravastatin, rosuvastatin, fluvastatin, or pitavastatin as alternatives 1
When switching statins, the American Heart Association recommends ensuring equivalent dosing for lipid-lowering effect 1

Failing to ask about grapefruit consumption when prescribing statins, particularly simvastatin and lovastatin, is a common pitfall to avoid, according to the American Heart Association 1
Assuming all statins have the same level of interaction with grapefruit juice is incorrect, as stated by the American Heart Association 1

Rosuvastatin is primarily eliminated unchanged in urine and feces through active transport mechanisms, including OATP1B1/3, breast cancer resistance protein, and OAT3, rather than through CYP3A4 metabolism, according to the American Heart Association guidelines 7, 8

The European Society of Cardiology recommends that patients with multiple interacting medications, such as macrolides, azole antifungals, or calcium channel blockers, exercise stricter caution when consuming grapefruit while taking atorvastatin 9, 10
Patients with chronic kidney disease, especially diabetic nephropathy, should be cautious when consuming grapefruit while taking atorvastatin, as they are at elevated risk 10

The American Heart Association suggests that patients who cannot limit grapefruit consumption may be switched to pravastatin, which is metabolized by non-CYP pathways and has minimal interaction with grapefruit 10
Rosuvastatin, which is primarily eliminated unchanged via OATP1B1/3 transport and not CYP3A4, is another alternative for patients who consume grapefruit 10
Fluvastatin and pitavastatin are also options, as they have minimal CYP450 metabolism and are less likely to interact with grapefruit 10

Grapefruit juice strongly inhibits intestinal CYP3A4, markedly raising plasma concentrations of statins that rely on this enzyme for metabolism. 11
Grapefruit juice also inhibits the drug‑transport protein P‑glycoprotein (P‑gp), which can further increase exposure of statins that are P‑gp substrates. 11

Simvastatin and lovastatin are extensively metabolized by CYP3A4; concomitant grapefruit juice produces a 12–16‑fold increase in drug exposure. 11
Atorvastatin undergoes CYP3A4 metabolism as a minor route and shows an ~80 % rise in plasma levels when taken with grapefruit juice. 11
These statins (simvastatin, lovastatin, atorvastatin) are also P‑gp substrates, which compounds the interaction potential. 11
Rosuvastatin is eliminated largely unchanged via hepatic OATP1B1/3 transporters, with only minimal CYP2C9 metabolism and no CYP3A4 involvement, rendering it insensitive to grapefruit‑induced CYP3A4 inhibition. [11][12]
Pravastatin is cleared through non‑CYP pathways, making grapefruit juice unlikely to affect its pharmacokinetics. 11
Fluvastatin and pitavastatin are primarily metabolized by CYP2C9 rather than CYP3A4, so grapefruit juice has minimal impact on their exposure. [11][12]

For patients who regularly consume grapefruit or grapefruit juice, rosuvastatin is a preferred option because it is not metabolized by CYP3A4 and only 10 % of the dose is renally excreted, minimizing interaction risk. 11
Pravastatin, fluvastatin, and pitavastatin also represent safe alternatives for individuals who cannot avoid grapefruit, given their non‑CYP3A4 metabolic pathways. [11][12]